- Home
- IONS vs CADE Comparison
IONS vs CADE Comparison
Compare IONS & CADE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CADE
- Stock Information
- Founded
- IONS 1989
- CADE 1876
- Country
- IONS United States
- CADE United States
- Employees
- IONS N/A
- CADE N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CADE Major Banks
- Sector
- IONS Health Care
- CADE Finance
- Exchange
- IONS Nasdaq
- CADE Nasdaq
- Market Cap
- IONS 6.0B
- CADE 6.4B
- IPO Year
- IONS 1991
- CADE N/A
- Fundamental
- Price
- IONS $32.32
- CADE $33.02
- Analyst Decision
- IONS Buy
- CADE Buy
- Analyst Count
- IONS 19
- CADE 11
- Target Price
- IONS $61.24
- CADE $38.73
- AVG Volume (30 Days)
- IONS 1.7M
- CADE 1.0M
- Earning Date
- IONS 02-19-2025
- CADE 01-22-2025
- Dividend Yield
- IONS N/A
- CADE 3.32%
- EPS Growth
- IONS N/A
- CADE N/A
- EPS
- IONS N/A
- CADE 2.77
- Revenue
- IONS $705,000,000.00
- CADE $1,721,725,000.00
- Revenue This Year
- IONS N/A
- CADE N/A
- Revenue Next Year
- IONS $10.08
- CADE $7.60
- P/E Ratio
- IONS N/A
- CADE $11.97
- Revenue Growth
- IONS N/A
- CADE 49.07
- 52 Week Low
- IONS $30.23
- CADE $26.16
- 52 Week High
- IONS $52.34
- CADE $40.20
- Technical
- Relative Strength Index (RSI)
- IONS 48.36
- CADE 34.97
- Support Level
- IONS $30.86
- CADE $32.89
- Resistance Level
- IONS $34.74
- CADE $35.61
- Average True Range (ATR)
- IONS 1.35
- CADE 0.77
- MACD
- IONS 0.18
- CADE -0.20
- Stochastic Oscillator
- IONS 46.34
- CADE 4.64
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About CADE Cadence Bank
Cadence Bank is a bank based in the United States. The operating segments are Corporate Banking segment focuses on C&I, business banking, and commercial real estate lending to clients in the geographic footprint, Community Banking segment provides a broad range of banking services through the branch network to serve the needs of community businesses and individual consumers in the geographic footprint, Mortgage segment includes mortgage banking activities of originating mortgage loans, selling mortgage loans in the secondary market and servicing the mortgage loans, Banking Services segment offers individuals, businesses, governmental institutions, and non-profit entities a widerange of solutions to help protect, grow, and transfer wealth, General Corporate and Other segment.